Search results
Showing 4981 to 4995 of 5059 results for technology
NICE has joined a global group of organisations whose goal is to speed up the development and delivery of new, effective and affordable drugs to patients.
NICE joins international collaboratives to respond to the COVID-19 pandemic
NICE is supporting a growing number of international collaborations to share knowledge and identify treatments in response to the COVID-19 pandemic.
NICE is getting ready for the end of the transition period after Brexit
NICE has a key role in evaluation and access to new and innovative products for the health system, playing an important role in ensuring the UK remains a destination of choice for the life sciences sector.
NICE local formularies guide will 'reduce variation in prescribing'
NICE has produced a good practice guide to help trusts develop and update local formularies, as part of a move to ensure that all patients in England have access to clinically and cost-effective drugs.
SIX health technology assessment (HTA) bodies from three continents are to collaborate on a range of topics that will benefit people accessing healthcare around the world.
NICE proposes simplifying how medicines and medical devices are selected for evaluation.
As part of the work underway to review the methods and processes NICE uses to develop guidance on medicines, medical devices and diagnostics, NICE has launched a public consultation on proposals for changing how it selects the topics it will develop guidance on.
NICE publishes its first medtech briefing on artificial intelligence software
NICE publishes a Medtech Innovation Briefing on artificial intelligence for analysing CT brain scans
Changes to the way medicines and other health technologies are evaluated by NICE have now been incorporated into NICE’s new combined methods and processes manual and topic selection manual published today (31 January 2022).
Around 1,500 people in England with the rare genetic disorder spinal muscular atrophy are set to benefit from a new treatment after NICE today (19 November 2021) published draft guidance recommending risdiplam (also called Evrysdi and made by Roche) as part of a managed access agreement (MAA).
NICE draft guidance recommends new treatment option for people with early breast cancer
NICE has today (7 May 2020) published draft guidance which recommends trastuzumab emtansine (also called Kadcyla and made by Roche) as an option for some people with HER2-positive early breast cancer.
NICE has today (25 February 2021) issued draft guidance for public consultation which recommends sapropterin (also called Kuvan and made by BioMarin) for treating phenylketonuria (PKU) in children aged up to 18.
NICE draft guidance recommends siponimod for treating secondary progressive multiple sclerosis
NICE has today (15 October 2020) issued draft guidance which now recommends siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).
NICE draft guidance recommends tucatinib for advanced breast cancer
Taken as two 150 mg tablets twice daily together with anti-cancer medicines trastuzumab and capecitabine, tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading.
NICE explores extending its use of data to inform its guidance
Consultation on proposal open until Friday 13 September
Research and knowledge sharing key to collaborative working approach agreed the two agencies